{
    "output": [
        [
            "bluebird bio Inc",
            "COMP",
            "Announce",
            "filing for regulatory approval",
            "EVENT"
        ],
        [
            "bluebird bio Inc",
            "COMP",
            "Operate_In",
            "Biotech sector",
            "SECTOR"
        ],
        [
            "Nick Leschly",
            "PERSON",
            "Is_Member_Of",
            "bluebird bio Inc",
            "COMP"
        ],
        [
            "bluebird bio Inc",
            "COMP",
            "Expects",
            "filing for approval this year",
            "EVENT"
        ],
        [
            "bluebird bio Inc",
            "COMP",
            "Expects",
            "filing for U.S. and European approval of b2121 in 2019",
            "EVENT"
        ],
        [
            "bluebird bio Inc",
            "COMP",
            "Develop",
            "treatment for transfusion-dependent beta thalassemia",
            "PRODUCT"
        ],
        [
            "bluebird bio Inc",
            "COMP",
            "Develop",
            "CAR-T therapy for multiple myeloma",
            "PRODUCT"
        ],
        [
            "Celgene Corp",
            "COMP",
            "Participates_In",
            "development of CAR-T therapy for multiple myeloma",
            "PRODUCT"
        ],
        [
            "bluebird bio Inc",
            "COMP",
            "Develop",
            "treatment for a rare and deadly genetic brain disorder, cerebral adrenoleukodystrophy",
            "PRODUCT"
        ],
        [
            "bluebird bio Inc",
            "COMP",
            "Cause",
            "stir at the American Society of Hematology meeting",
            "EVENT"
        ],
        [
            "bluebird bio Inc",
            "COMP",
            "Develop",
            "promising treatment for sickle cell disease",
            "PRODUCT"
        ],
        [
            "bluebird bio Inc",
            "COMP",
            "Looking_To_Develop",
            "right pricing and reimbursement strategy",
            "CONCEPT"
        ],
        [
            "Novartis",
            "COMP",
            "Price",
            "first approved CAR-T treatment for other cancers",
            "PRODUCT",
            "at",
            "$475,000",
            "ECON_INDICATOR"
        ],
        [
            "Gilead Sciences",
            "COMP",
            "Price",
            "first approved CAR-T treatment for other cancers",
            "PRODUCT",
            "at",
            "$373,000",
            "ECON_INDICATOR"
        ]
    ]
}